Envisagenics Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
47
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$25M
- Investors
-
23
Envisagenics General Information
Description
Developer of a bioinformatics platform intended to accelerate the development of novel therapeutics. The company's platform incorporates advanced artificial intelligence and machine learning algorithms to analyze, predict, and interpret transcriptomic data, enabling researchers to identify and validate potential drug targets.
Contact Information
Website
www.envisagenics.comCorporate Office
- 30-02 48th Avenue
- Suites 140 and 150
- Long Island City, NY 11101
- United States
Corporate Office
- 30-02 48th Avenue
- Suites 140 and 150
- Long Island City, NY 11101
- United States
Envisagenics Timeline
Envisagenics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series B) | 04-Jun-2024 | $25M | Completed | Pre-Clinical Trials | ||
| 9. Debt - General | 17-May-2023 | Completed | Pre-Clinical Trials | |||
| 8. Grant | 02-Aug-2022 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC (Series A) | 24-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 6. Debt - PPP | 01-May-2020 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 12-Sep-2019 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 05-Apr-2018 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 30-Nov-2017 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 06-Aug-2015 | $225K | $100K | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | 27-Jul-2015 | $100K | $100K | Completed | Pre-Clinical Trials |
Envisagenics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 6,964,570 | $0.000100 | $0.03 | $0.43 | $0.43 | 1x | $0.43 | 14.06% |
| Series A-1 | 277,760 | $0.000100 | $0.01 | $0.25 | $0.25 | 1x | $0.25 | 0.56% |
Envisagenics Comparisons
Industry
Financing
Details
Envisagenics Competitors (11)
One of Envisagenics’s 11 competitors is Deep Genomics, a Venture Capital-Backed company based in Toronto, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Deep Genomics | Venture Capital-Backed | Toronto, Canada | ||||
| Oxford Gene Technology | Formerly VC-backed | Begbroke, United Kingdom | ||||
| Cyclica | Formerly VC-backed | Toronto, Canada | ||||
| Diagenode | Formerly VC-backed | Seraing, Belgium | ||||
| Standard BioTools | Formerly VC-backed | San Francisco, CA |
Envisagenics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Envisagenics Patents
Envisagenics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4205121-A2 | Neoantigens, methods and detection of use thereof | Pending | 28-Aug-2020 | ||
| US-20230263872-A1 | Neoantigens, methods and detection of use thereof | Pending | 28-Aug-2020 | ||
| EP-4205121-A4 | Neoantigens, methods and detection of use thereof | Pending | 28-Aug-2020 | ||
| US-20220112497-A1 | Cancer-specific molecules and methods of use thereof | Pending | 09-Apr-2019 | ||
| AU-2020271530-A1 | Cancer-specific molecules and methods of use thereof | Pending | 09-Apr-2019 | C12N15/113 |
Envisagenics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Envisagenics Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bristol-Myers Squibb | Corporation | Minority | ||
| Myeloma Investment Fund | Not-For-Profit Venture Capital | Minority | ||
| National Institutes of Health | Government | |||
| Gillian Sandler | Angel (individual) | Minority | ||
| Hawktail | Venture Capital | Minority |
Envisagenics FAQs
-
When was Envisagenics founded?
Envisagenics was founded in 2014.
-
Where is Envisagenics headquartered?
Envisagenics is headquartered in Long Island City, NY.
-
What is the size of Envisagenics?
Envisagenics has 47 total employees.
-
What industry is Envisagenics in?
Envisagenics’s primary industry is Discovery Tools (Healthcare).
-
Is Envisagenics a private or public company?
Envisagenics is a Private company.
-
What is the current valuation of Envisagenics?
The current valuation of Envisagenics is .
-
What is Envisagenics’s current revenue?
The current revenue for Envisagenics is .
-
How much funding has Envisagenics raised over time?
Envisagenics has raised $40.5M.
-
Who are Envisagenics’s investors?
Bristol-Myers Squibb, Myeloma Investment Fund, National Institutes of Health, Gillian Sandler, and Hawktail are 5 of 23 investors who have invested in Envisagenics.
-
Who are Envisagenics’s competitors?
Deep Genomics, Oxford Gene Technology, Cyclica, Diagenode, and Standard BioTools are some of the 11 competitors of Envisagenics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
